Skip to main content
. Author manuscript; available in PMC: 2014 Jun 1.
Published in final edited form as: Cancer Res. 2013 Apr 10;73(11):3381–3392. doi: 10.1158/0008-5472.CAN-12-4047

Figure 2. Chronic erlotinib treatment generates resistant cells with a mesenchymal gene expression pattern.

Figure 2

A. Expression of GLI transcription factors are significantly increased in EGFR dependent cells chronically treated with 10μM erlotinib. B. Erlotinib resistant cells highly express pro-EMT genes after removal from selection media. C. Percentage of Vim-positive cells is significantly increased in erlotinib resistant cell lines, measured by flow cytometry D. Erlotinib resistant cells are not sensitized to HhP inhibition by IPI-926. Cells were treated with erlotinib (1,5,10μM) or IPI-926 (1,5,10μM) and proliferation was measured by the SRB assay. Sensitivity to erlotonib decreased in resistant cells while sensitivity to IPI-926 was unchanged. *P<0.05, **P<0.01.